Wednesday, January 26, 2022


Bharat Biotech completes phase 2 trials for kids

Hyderabad: Bharat Biotech completed the Phase 2/3 trials of Covid-19 vaccine, Covaxin for use in children under 18 years of age and is expected...

First commercial batch of Covaxin manufactured in Ankleshwar launched

Union minister of Health and Family Welfare Mansukh Mandaviya formally launched the Covaxin batches. Dr Krishna Ella, CMD, Bharat Biotech and Suchitra Ella, joint managing director, Bharat Biotech were also present at the launch.

Editorial: Boost to vaccination drive

Nod for Zydus Cadila'd Covid vaccine for children will help India ramp up its vaccination programme quickly

Indian Immunologicals ramping up Covaxin drug substance production

Output of Covaxin drug substance will be adequate for 3 to 4 million doses a month and from December it will increase to 10 million doses a month

Editorial: Mixing vaccines

It is argued that such a mixed regimen will help overcome the challenges of the shortfall of certain vaccines and remove hesitancy, especially in settings where multiple Covid-19 vaccines are being used

India’s drug regulator approves study on mixing of Covaxin and Covishield doses

An expert panel of the Central Drugs Standard Control Organisation (CDSCO) on July 29 had recommended granting permission for conducting the study.

Bharat Biotech’s Ankleshwar unit gets nod to make Covaxin

Bharat Biotech recently stated that products manufactured from Ankleshwar will be available for supplies during September.

Hyderabad: Special offer for Covaxin in Apollo Hospitals from Aug 12-21

Under the special freedom offer, Apollo Hospitals will offer the Covaxin vaccine at a no profit cost price of Rs.1,250.

Mixing Covishield, Covaxin provides better immunity: ICMR

The results of a study conducted by ICMR showed that the people in the mix and match group had superior immunogenicity profiles against Alpha, Beta and Delta variants of Covid-19

Covaxin under review process in Canada: Bharat Biotech’s partner Ocugen

Ocugen said Bharat Biotech completed and posted its phase 3 clinical trial results for Covaxin demonstrating 77.8 per cent efficacy against overall Covid-19 disease

Bharat Biotech allays fears over quality of Covaxin

Says supply of nearly 70 million doses of its Covid-19 vaccine to date proves its safety standards

Covaxin receives Good Manufacturing Practice certificate from Hungary

The approval has been received from the National Institute of Pharmacy and Nutrition, Hungary, certifying the GMP for the manufacture of Covaxin.

Editorial: Double the vaccination rate

More than half of the adult population has yet to receive even a single dose, despite a slight improvement in coverage in July

Committed to supply 50 crore vaccine doses to Centre: Bharat Biotech

The company had supplied about four billion doses to about 125 countries and will continue to ramp up production at its four plants in the country, said Suchitra Ella, co-founder of Bharat Biotech

Vaccines reduce ‘Delta’ severity: Study

The rate of mortality was found to be about 50% lower in fully vaccinated individuals having a breakthrough infection, according to CCMB, AIg study

Latest News

- Advertisement -